The Bangladesh Securities and Exchange Commission (BSEC) has granted special approval to Beximco Pharmaceuticals to hold a board meeting, amid concerns over its potential delisting from the London Stock Exchange.

According to Dhaka Stock Exchange (DSE) sources, the approval was issued on Sunday (June 21), allowing the company to proceed with its delayed financial reporting process and declare dividends for the year ended June 30, 2025.

Following the approval, Beximco Pharma has scheduled a board meeting for Tuesday (June 23), where it will review the audited financial statements for the year ended June 2025 as well as quarterly reports for the ongoing fiscal year.

The company will also consider dividend declaration for shareholders during the meeting.

Regulatory sources said the company faced delisting risk from the London Stock Exchange’s Alternative Investment Market (AIM) due to delays in publishing audited financial statements. Trading of its Global Depository Receipts (GDRs) has been suspended on AIM since January 2 this year due to non-compliance with reporting deadlines.

Under AIM rules, a suspension of trading for six consecutive months may lead to cancellation of listing status. In this context, six institutional investors recently urged the BSEC chairman to facilitate a special arrangement allowing the company to hold its board meeting and approve pending financial reports.

In response, the regulator granted the special permission to help the company regularize its financial disclosures and address listing concerns in the London market.